Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

1 recruiting6 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 1

3(37.5%)

Phase 3

1(12.5%)

8Total

Phase 2(4)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04588922Phase 1Recruiting

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Role: lead

NCT05593185Unknown

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Role: lead

NCT04229979Phase 3Active Not Recruiting

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Role: lead

NCT03761914Phase 1Completed

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Role: lead

NCT01266083Phase 2Completed

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Role: lead

NCT01265433Phase 2Completed

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

Role: lead

NCT01827137Phase 1Completed

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Role: lead

NCT02297698Phase 2Completed

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Role: collaborator

NCT01570036Phase 2Completed

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Role: collaborator

All 9 trials loaded